Latest Management of prostate cancer Stories
First study to show that the genomic signature of prostate cancer can predict rapid development of metastatic disease in men who were managed conservatively after surgery SAN DIEGO, Dec.
Statement from the primary funder, the Movember Foundation, in response to the research paper - Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence
PATIENT SELECTION PREDICTS EXCELLENT PROSTATE CANCER TREATMENT SARASOTA, Fla., Nov.
Opportunities Being Developed While the Situation with the PCA3 Prostate Cancer Test is Being Resolved QUEBEC CITY, Oct. 30, 2014 /PRNewswire/ - DiagnoCure, Inc.
SonaCare Medical, LLC, leader in minimally invasive high intensity focused ultrasound (HIFU) technology, announced that its Board of Directors has appointed Dr. Mark Carol, M.D.
SonaCare Medical FDA Panel Review for Its Sonablate® 450 Prostate Ablation System CHARLOTTE, NC (PRWEB) October 03, 2014 FRIDAY, OCTOBER 3, 2014
Final data after 49-month follow-up analysis in chemotherapy-naïve men with metastatic castration-resistant prostate cancer presented at European Society for Medical Oncology (ESMO) 2014 Congress
Final analysis of Phase 3 COU-AA-302 study presented at the European Society for Medical Oncology (ESMO) 2014 Congress HORSHAM, Pa., Sept.
Oral presentation at American Society for Radiation Oncology Annual Meeting describes Decipher's ability to identify high-risk prostate cancer patients that may benefit from radiation therapy after
- The act of sweetening by admixture of some saccharine substance.